StockNews.com began coverage on shares of Clovis Oncology (NASDAQ:CLVS – Get Rating) in a research report sent to investors on Monday. The firm issued a hold rating on the biopharmaceutical company's stock.
Separately, JPMorgan Chase & Co. downgraded Clovis Oncology from a neutral rating to an underweight rating in a report on Wednesday, November 9th.
Get Clovis Oncology alerts:Clovis Oncology Price Performance
Clovis Oncology has a 52-week low of $0.08 and a 52-week high of $3.32. The business's fifty day moving average price is $0.56 and its two-hundred day moving average price is $1.15.
Clovis Oncology (NASDAQ:CLVS – Get Rating) last released its earnings results on Wednesday, November 9th. The biopharmaceutical company reported ($0.39) earnings per share for the quarter, topping analysts' consensus estimates of ($0.42) by $0.03. The firm had revenue of $30.66 million for the quarter, compared to the consensus estimate of $34.79 million. On average, equities research analysts predict that Clovis Oncology will post -1.68 earnings per share for the current fiscal year.Institutional Investors Weigh In On Clovis Oncology
Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Swiss National Bank grew its stake in Clovis Oncology by 17.9% in the first quarter. Swiss National Bank now owns 291,900 shares of the biopharmaceutical company's stock valued at $590,000 after acquiring an additional 44,400 shares during the period. WINTON GROUP Ltd acquired a new position in Clovis Oncology in the first quarter valued at about $179,000. Bank of Montreal Can acquired a new position in Clovis Oncology in the first quarter valued at about $48,000. Panagora Asset Management Inc. grew its stake in Clovis Oncology by 3.2% in the first quarter. Panagora Asset Management Inc. now owns 574,225 shares of the biopharmaceutical company's stock valued at $1,160,000 after acquiring an additional 18,000 shares during the period. Finally, Vanguard Group Inc. grew its stake in Clovis Oncology by 22.1% in the first quarter. Vanguard Group Inc. now owns 12,348,898 shares of the biopharmaceutical company's stock valued at $24,945,000 after acquiring an additional 2,233,797 shares during the period. Institutional investors own 24.53% of the company's stock.
About Clovis Oncology
(Get Rating)
Clovis Oncology, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. Its commercial product includes Rubraca (rucaparib) tablet, a small molecule poly ADP-ribose polymerase inhibitor, used as monotherapy for the treatment of patients with deleterious BRCA mutation associated advanced ovarian cancer, who have been treated with two or more chemotherapies, and selected for therapy by an FDA-approved companion diagnostic for Rubraca.
See Also
- Get a free copy of the StockNews.com research report on Clovis Oncology (CLVS)
- Your Decision to Buy Palantir May Simply Be a Matter of Time
- Are Caterpillar and Deere Setting Up to Rally in 2023?
- Mullen Automotive Gets a Jolt as the I-GO Arrives in Europe
- Will The Sun Shine On These 3 Large-Cap Solar Stocks In 2023?
- Lucid Motors Faces a Reality That May Cloud a Bullish Perception
Receive News & Ratings for Clovis Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clovis Oncology and related companies with MarketBeat.com's FREE daily email newsletter.